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Exogenous Surfactant 
Treatment in Children 
with ARDS
ABSTRACT
Since the Food and Drug Administration (FDA) approved exogenous surfactant in the early 90s for the treatment of neonates 
with Hyaline Membrane Disease (HMD), many studies have focused on enlarging its indications for others types of lung 
injuries and for other age groups. Although in the past 20 years no studies have shown clear results about the efficacy of 
exogenous surfactant treatment in paediatric Acute Respiratory Distress Syndrome (ARDS), many of them were able to 
point out and better define very important aspects of this treatment like dosage, timing, ways of administration and usage of 
different types of surfactant (natural and synthetic). In this review we retrace the development of studies looking at the role 
of exogenous surfactant treatment in paediatric ARDS.
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Introduction
Despite the development of many dif-
ferent therapeutic strategies (High Fre-
quency Oscillatory Ventilation - HFOV, 
Nitric Oxygen - NO, Non Invasive 
Mechanical Ventilation, surfactant and 
corticosteroids) for the management of 
Acute Respiratory Distress Syndrome 
(ARDS), none of them achieved sta-
tistically significant results in terms of 
beneficial effects on primary outcomes 
(1) and in paediatric patients, with ARDS 
mortality remaining high (>40%) in the 
last 10 years. (1-4) Among the various 
strategies used to fight ARDS, treatment 
with exogenous surfactant is supported 
by the strongest experimental evidence: 
in many animal models of ARDS, (5-9) 
and in children with ARDS, (1,4,10-
12) it is clearly evident that synthesis 
of surfactant is decreased while sur-
factant inactivation and consumption is 
increased. The alveoli of ARDS children 
show a lack of surfactant active forms 
(large aggregates) and an increase in 
small aggregates that are the catabolic 
products of surfactant and are func-
tionally inactive. (4) This impairment in 
surfactant function is closely associated 
with alterations in pulmonary function 
that characterize children with ARDS. (4) 
Although in animal models the adminis-
tration of exogenous surfactant is able 
to change the course of ARDS, when 
it is studied in children its beneficial 
effect is weak or totally absent. (4-12) 
We would like to analyze the reasons for 
this, focusing our attention on dosage, 
modality of administration and type of 
surfactant used. ARDS is different from 
HMD and treatment differs.
ARDS Pathophysiology
Acute respiratory distress syndrome is 
a lung pathology induced by diverse 
injuries, including trauma, sepsis, liq-
uid aspiration, inhaled gases, radia-
tion, pneumonitis and many others. 
ARDS is characterised by damage to 
the arteriolar-capillary endothelium and 
alveolar epithelium, including type I 
and type II pneumocytes. (3) Damage 
to the latter results in surfactant defi-
ciency and atelectasis. Even though 
surfactant abnormalities in ARDS are 
not the primary pathogenic factor, sur-
factant deficiency, either in the pres-
ence or absence of type II pneumocyte 
alterations, may result from primary or 
secondary inhibition or inactivation of 
pulmonary surfactant in the alveolar 
space. (3-13) Surfactant deficiency and 
inactivation will further induce alveolar 
collapse and pulmonary oedema, lead-
ing to the characteristic pathophysiol-
ogy of ARDS. (3-13)
ARDS was first described in 1967. (14) It 
is characterized by fast, acute develop-
ment of clinically significant hypoxemia, 
with the appearance of diffuse pulmo-
nary infiltrates, such as seen in the case 
of lung edema. Edema results from 
increased vascular permeability, which 
does not appear due to left-side cardiac 
impairment or increased pressure in the 
left atrium (pulmonary wedge pressure 
is lower than 18 mmHg). With regard 
to the level of hypoxemia, we distin-
guish between the milder form, where 
the ratio between the partial oxygen 
pressure in arterial blood and inspired 
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oxygen concentration (PaO2/FiO2) is 
between 300 and 200, and the severe 
form, named ARDS, where the PaO2/
FiO2 ratio is lower than 200. (15) This 
definition has been recently revised 
as the ‘Berlin Definition’ and was pub-
lished in JAMA. An important factor in 
ARDS development is probably also 
genetic predisposition, which contrib-
utes to the response of the organism to 
direct or indirect triggers of lung impair-
ment. Observed direct triggers include 
pneumonia, drowning, aspiration of 
stomach contents, inhalation of smoke 
or irritant gases, fat embolism, thoracic 
bruise and alveolar hemorrhage, while 
indirect causes include, among others, 
sepsis, transfusion, shock, pancreati-
tis and overdose of salicylates or nar-
cotics. ARDS can affect patients of all 
ages. (15) Therapy is primarily oriented 
toward the treatment of hypoxemia, and 
identification and treatment of the direct 
cause of respiratory distress. (16)
In the case of newborns and babies, 
severe forms of respiratory failure 
(ARDS) can be treated by high-frequen-
cy oscillatory ventilation, and when 
severe pulmonary hypertension is pres-
ent, we add a selective dilator of pulmo-
nary vessels, NO gas in doses of 20 to 
40 parts per million (ppm). Exogenous 
surfactant is also used for newborns 
and babies, as ARDS involves second-
ary deficiency of the natural surfactant, 
which results in lung collapse. (17)
In the last 10 years, the use of exog-
enous surfactant in the treatment of 
respiratory disorder of newborns has 
significantly reduced the mortality of 
premature babies; nevertheless, it 
remains the main cause of death of 
such infants. Respiratory distress suf-
fered by a newborn, results from two 
pathophysiological mechanisms: sur-
factant deficiency and action of sur-
factant inhibitors. (4-17) After birth, 
the lungs of neonates are still full of 
fluid, and functionally and morphologi-
cally immature. They have low func-
tional residual capacity and insufficient 
amount of surfactant. (4-17)
Surfactant Treatment
Pulmonary surfactant used as a 
medicinal product is a natural surface-
active substance obtained from ani-
mal lungs (e.g. porcine surfactant). It 
contains almost exclusively phospho-
lipids, especially phosphatidylcholine 
(approximately 70% of the total con-
tent of phospholipids) and around 1% 
of specific low-molecular hydropho-
bic proteins SP-B and SP-C. (18) The 
surface-active substance in the alveoli 
mostly consists of phospholipids and 
specific proteins. It covers the inner 
surface of the alveoli, with its principal 
task being to reduce surface tension in 
the lungs. (18) The reduction of surface 
tension is crucial for the stabilization of 
the alveoli and prevention of their col-
lapse at the end of an exhale, so that 
adequate gas exchange is maintained 
throughout the ventilation cycle. (18)
Regardless of the cause, deficiency of 
this surface-active agent in the alveoli 
of premature neonates results in severe 
respiratory insufficiency, known as 
respiratory distress syndrome (RDS) or 
hyaline membrane disease. RDS is the 
main cause of acute mortality and acute 
morbidity of newborns, and perhaps 
also responsible for long-term respira-
tory and neurological consequences. 
(18) When administered intratrachealy, 
the natural surfactant, as an exogenous 
surface-active substance, compen-
sates for the lack of the endogenous 
surface-active substance in the alveoli. 
The properties of a natural surfactant 
as a surface-active substance enable 
its even distribution in the lungs and 
spreading on the surfaces where air and 
fluid meet in the alveoli. The physiologi-
cal and therapeutic effects of a natural 
surfactant in the case of surface-active 
substance deficiency in the alveoli are 
extensively documented for various ani-
mal models. In all studies published, no 
safety concerns have been reported. 
(18) There were no adverse drug reac-
tions (ADRs), namely events that were 
considered by neonatologists to be 
related to study treatment. The report-
ed adverse events (AEs) were those 
typically associated with prematurity. 
More than three hundred publications 
can be selected in PubMed using the 
search term “Curosurf or poractant 
alfa”. Literature confirms that surfactant 
therapy is the standard of care in the 
management of preterm neonates with 
RDS, a specific disease of premature 
neonates. The benefits of surfactant 
treatment, including the reduction of 
mortality and incidence of pulmonary 
air leaks, especially of pneumothorax, 
in neonates suffering from RDS, coun-
terpoise any risks.
Paediatric studies
Compared to neonates, only a few 
studies or case reports have been pub-
lished on the use of surfactant in criti-
cally ill children or adults with ARDS. No 
specific risks were described in all these 
papers.  Despite discouraging findings 
in adults, (19) most of them  due to evi-
dent bias in term of type of surfactant, 
(20) dosage and way of administration, 
(20) the first studies published using 
surfactant in paediatric ARDS were able 
to underline some important issues: 1) 
a trend to improve gas exchange and 
pulmonary mechanics early after sur-
factant instillation in the  endotracheal 
tube; 2) a dilution of this effect over time 
with a return after 12-24 hours to the 
pre-surfactant treatment situation; 3) 
no or few effects on primary outcomes, 
such as duration of mechanical ventila-
tion, Intensive Care Unit (ICU) length 
of stay (LOS) and mortality. (19) Com-
pared to adults, the weakness of paedi-
atric studies included the small sample 
size of the enrolled patients and their 
heterogeneity in age and weight. (19) 
On the other hand, paediatrics patients 
were much more homogenous than 
adults in regard to underlying diseases 
(primary and secondary lung injuries), 
way of administration (endotracheal 
instillation), dosages (range 50- 100 
mg/kg) and type of surfactant used 
(all used natural surfactant with ade-
quate concentration of protein).  (19) 
Willson and Luchetti (21,22) focused 
their attention on primary lung injured 
patients and on a restricted group of 
babies with brochiolitis (those were 
also more homogenous in terms of age 
and weight). They were able to show a 
beneficial effect of exogenous natural 
surfactant treatment on primary out-
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come as days on mechanical ventila-
tion, days of ICU LOS and mortality. The 
same studies were utilized and ana-
lysed by Duffet in his meta-analysis in 
2007. (19) He confirmed that in children 
on mechanical ventilation with primary 
lung injuries, endotracheal instillation 
of 50-100 mg/kg of surfactant reduced 
days of mechanical ventilation, days of 
ICU LOS and in some way, mortality. 
These results are much more encour-
aging compared to the failure of using 
surfactant in adult ARDS as reported 
in 1996 by Anzueto in his randomized 
control trial (RCT). (23) He enrolled 
more than 400 patients but he used a 
synthetic surfactant with no proteins 
and he administered it by aerosoliza-
tion over 24 hours via the endotracheal 
tube. Later this strategy resulted in less 
than 5% of a not very active surfactant 
reaching the ARDS alveoli. (20) Other-
wise Anzueto’s study weight in terms of 
sample size influenced for a long period 
of time the negative feeling about exog-
enous surfactant treatment in ARDS out 
of the neonatal age. After Duffet’s meta-
analysis, no other randomized control-
led trials were published on the topic in 
paediatric patients except Willson’s trial 
published just last month. Unexpect-
edly it showed no benefit of using Cal-
factant in children with direct lung injury, 
overturning the findings of their previ-
ous studies. They concluded it may 
have occurred due to weak distribution 
caused by the absence of recruitment 
manoeuvres, increased concentration 
and less volume of Calfactant solution 
used in the study. They also enrolled 
an extremely heterogeneous group of 
children aging 2 months to 18 years. 
This study highlighted all the difficul-
ties associated with arranging a good 
quality RCT with an adequate sample 
size. The need for  huge,  multicentre 
trials developing over a long period 
of time and facing heterogeneity  in 
regards to case definition, underlying 
disease, age, associated strategy of 
treatment, sets of mechanical ventila-
tion etc. with the high risk of spending 
a lot of resources and time and having 
little prospects of getting clear results, 
restrained researchers from planning 
such a study. On the other hand, some 
experimental studies (24-30) specu-
lated that endotracheal instillation 
could not be the best way of surfactant 
administration in ARDS lungs, argu-
ing that especially in the latest stage, 
ARDS lungs are unevenly ventilated 
with part of the alveoli completely filled 
of inflammatory proteins, cells and 
debris. This prevented homogenous 
distribution of surfactant in all regions 
of the lungs and moreover, most of 
these inflammatory factors are strong 
surfactant inactivators decreasing rap-
idly over time the efficacy of exogenous 
surfactant treatment. (4) In different 
ARDS animal models, (24-29) broncho-
alveolar lavage compared to tracheal 
instillation showed a more powerful 
and more lasting beneficial impact on 
gas exchange. The best results were 
obtained when bronchoalveolar lavage, 
using a diluted surfactant solution, (24) 
was followed by a supplementation 
of exogenous surfactant with regular 
instillation. This procedure, increasing 
the volume of solution used until 10-15 
cc/kg, was able to: 1) achieve better 
distribution of exogenous surfactant 
in all alveoli despite their nonnhomo-
geneity, 2) reduce the total amount of 
surfactant utilized and 3) use the deter-
gent proprieties of surfactant as a safe, 
soft and potent lavage solution. A total 
volume above 10cc/kg could generate 
side effects such as hypoxia, bradycar-
dia, impairments of gas exchange and 
vagal reflex. (29) These animal stud-
ies on exogenous surfactant lavages 
are very impressive but in the literature 
there are no trials in humans except 
for a few small studies done in adults 
and in older children using the bron-
choscope. (31-33) The bronchoscope 
allows reduction of the total volume 
of lavages to 1-3 cc/kg, decreasing 
side effects from larger volumes but it 
requires a lot of expertise in the man-
agement of such respiratory unstable 
patients during this invasive procedure. 
Nevertheless, in treated subjects most 
of the studies showed an improvement 
in gas exchanges. 
In smaller infants, the only study using 
diluted surfactant via bronchoalveo-
lar lavage was done in neonates with 
Meconium Aspiration Syndrome (MAS). 
(34) In this model, nonnhomogene-
ity of aerated versus collapsed areas 
of lungs, presence of inflammatory 
factors, inactivation of surfactant and 
severe lung injury are quite similar to the 
ARDS situation: MAS neonates suffered 
more from inactivation of surfactant 
than from a deficit of its synthesis. This 
RCT showed that in this category of 
neonates with severe lung injury, bron-
choalveolar lavage with exogenous sur-
factant was able to reduce the need 
for extra corporal membrane oxygena-
tion (ECMO) and mortality in hospital 
without ECMO, in respect to standard 
of care. Furthermore, we found many 
case reports describing bronchoal-
veolar lavage with diluted surfactant 
in ARDS children using, either bron-
choscope manoeuvres (older child) or 
direct tracheal lavages (smaller child). 
Despite ARDS, the etiology was very 
different (sepsis, near drowning, trau-
ma, and aspiration syndrome) and all 
of them showed a rapid decrease of 
ventilator settings and improvement 
of lung mechanics after the treatment. 
Primary outcomes were not evaluated. 
(30,32,35,36) 
Recently we reported 14 patients with 
severe ARDS (Oxygen Index > 20) not 
responding to HFOV, NO or corticoster-
oids that took advantage of bronchoal-
veolar lavages with diluted surfactant 
(8mg/ml) done 3 times in the 3 different 
classic positions. Gas exchange and 
pulmonary mechanics improved rap-
idly after the procedures and in half of 
the patients a second treatment was 
needed after a median time of 12 hours. 
No side effects were reported and these 
results were presented at ESPR 2007 in 
Prague. (30)
Conclusion
Although recent preliminary studies 
using surfactant bronchoalveolar lavag-
es in paediatric patients with ARDS are 
encouraging, no definitive results were 
obtained and a RCT facing questions 
about time, dosage and way of admin-
istration has not yet been done.  The 
major reasons for this are: 1) high cost 
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of exogenous surfactant; 2) difficulty in 
planning a suitable trial; 3) no specific 
therapeutic indication in children with 
the absence of standardization for tim-
ing, dosage and way of administration. 
All these factors are strictly correlated 
and the absence of an indication and 
standardization in children with ARDS 
has resulted in most paediatric inten-
sivists using it only on an experimental 
basis in neonates with severe ARDS 
not responding to all other therapies. 
This means, to face ARDS in the latest 
stages when lungs become very inho-
mogenous, full of inflammatory factors 
obstructing alveoli and lower airways. 
In this advanced state, inflammatory 
factors that fill alveoli inactivate eas-
ily most of the endogenous surfactant 
further worsening lung injury and gas 
exchange. (13) Late treatment has a 
high risk of failure due to few substanc-
es reaching the alveoli. Moreover, the 
small amount of exogenous surfactant 
that reaches the airways peripherally is 
rapidly inactivated. (4) Surfactant bron-
choalveolar lavage seems to act better 
than simple instillation because it uses 
a larger volume and has better periph-
eral distribution especially in severely 
injured lungs. (37) Bronchoalveolar lav-
age cleans up inflammatory factors 
that inactivate surfactant and reduce 
the dosage of exogenous surfactant 
left in the lungs after lavage. There is 
no standardized dose of natural exog-
enous surfactant either for lavages or 
for supplementation but most authors 
used a 10 times diluted solution of 
surfactant (5 to 10 mg/ml) with a total 
volume of 3 to 5 cc / kg, leaving in the 
lungs, at the end of the procedure, 25 
mg to 50 mg /kg of natural surfactant as 
supplementation. 
Using exogenous surfactant in the early 
stage of ARDS could be associated 
with lower dosage, better distribution 
and better efficacy. When lungs are 
less injured, other ways of administra-
tion could also be used, such as simple 
instillation or aerosolization because 
some new experimental studies (38-
40) have shown a good distribution 
of these less invasive tools especially 
when lungs have not yet deteriorated.
Other investigations in exogenous sur-
factant treatment in ARDS examined 
the possibility of using different types 
of synthetic surfactant. (41) A recent 
type of synthetic exogenous surfactant 
seems to overcome the old problem 
related to their scares efficacy. This 
new synthetic surfactant has a syn-
thetic protein which seems to be more 
resistant to inactivation. We can specu-
late that in the near future there will be 
different types of synthetic surfactant 
available for different types of lung ill-
nesses and for different methods of 
administration (aerosol vs. instillation 
vs. lavages). To verify all the possible 
developments of exogenous surfactant 
treatments with definitive results and 
to standardize it according to timing, 
way of administration, stage of illness, 
type of surfactant used and ARDS 
handling associated strategy, will be 
very  difficult. To design a rigorous 
trial, RCT, with a high risk of generat-
ing an extremely long, expensive and 
uninterpretable study will be challeng-
ing. Small experimental studies done 
with stable isotopes are promising and 
have already given us important data 
regarding endogenous and exogenous 
surfactant turn over and metabolism in 
premise, neonates and children with 
and without lung injury. (24-44) Stable 
isotopes could be very accurate for 
individualizing the correct timing, route 
of administration and dosage of differ-
ent types of surfactant.
There is no magic bullet for managing 
ARDS in children. This is a multifactorial 
disease and different strategies have to 
act at different levels to deal with all the 
problems associated with ARDS and 
underlying diseases that often match 
with this lung injury. Exogenous sur-
factant could be one of these strategies 
helping to improve pulmonary mechan-
ics and gas exchange and decreasing 
the need for mechanical ventilation that 
in turn consumes surfactant and wors-
ens lung injury in the classical bimodal 
process of ARDS. Breaking this vicious 
cycle could be a key element in over-
coming ARDS. In 2004 an editorial in 
the New England Journal of Medicine 
(45-47) was wondering why surfactant 
treatment in ARDS is still a matter of 
discussion despite the majority of trials 
done in the last 10 years showing no 
beneficial effects on primary outcome. 
Now we can affirm that surfactant’s 
special status as “substance under 
prolonged investigation” suggests a 
new and interesting aspect extending it 
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